IQ-AI Limited IMAGING BIOMETRICS UPGRADES IB CLINIC(TM) SOFTWARE (5438G)
November 26 2020 - 2:00AM
UK Regulatory
TIDMIQAI
RNS Number : 5438G
IQ-AI Limited
26 November 2020
26 November 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
IMAGING BIOMETRICS UPGRADES IB CLINIC(TM) SOFTWARE
IQ-AI today announces that its subsidiary, Imaging
Biometrics(R), LLC (IB), has made available release 20.11 of its IB
Clinic(TM) software platform. The new release incorporates multiple
new enhancement requests received from clients, as well as workflow
efficiencies engineered by IB's developers. Ultimately, this
release underscores IB's commitment to quality and helping
clinicians improve care for their patients.
IB Clinic consists of perfusion weighted imaging and
permeability computation modules IB Neuro and IB DCE, diffusion
weighted imaging analysis module IB Diffusion, image
co-registration and manipulation module IB Delta Suite, and IB Rad
Tech, which streamlines and automates customizable workflows. While
the products contained in IB Clinic continue to be available as
plugins to the Mac-based medical imaging viewers, aycan workstation
and OsiriX MD, they are also now available as platform-independent
automated applications for both in-house and cloud-based
processing. Both options generate consistent quantitative output
regardless of where or when a patient is scanned, a feature unique
to IB Clinic.
"This latest release further builds upon our proven track record
of delivering scientifically proven advancements to clinicians,"
said Michael Schmainda, CEO of IB.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
ABOUT Imaging Biometrics , LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent and automated software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUBABLTMTMTBIM
(END) Dow Jones Newswires
November 26, 2020 02:00 ET (07:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024